Recent Update,IRBP derived peptide, R16

The irbp peptide, specifically fragments derived from the Interphotoreceptor Retinoid Binding Protein (IRBP), plays a crucial role in understanding and potentially treating various retinal conditions. IRBP, also known as RBP3, is a large, glycoprotein that resides in the interphotoreceptor matrix of the eye. It is secreted by photoreceptor cells and is vital for the survival of these cells and the visual cycle. Research into IRBP derived peptide and specific IRBP-derived peptide sequences has shed light on its involvement in immune responses within the eye, particularly in the context of experimental autoimmune uveitis (EAU).

IRBP is recognized as a major uveitogenic retinal antigen. This means that when the immune system encounters certain irbp peptide sequences, it can trigger an inflammatory response in the eye, leading to EAU. Studies have identified specific epitopes within the IRBP molecule that are particularly potent in eliciting this immune response. For instance, the peptide 161-180 of human interphotoreceptor retinoid-binding protein (IRBP) has been identified as a major pathogenic T-cell epitope. This specific human IRBP peptide is able to induce EAU in animal models, particularly in mice with the H-2b haplotype. Another significant IRBP peptide fragment is IRBP (1-20), human, which also contains a major epitope for the H-2b haplotype and is known to induce experimental autoimmune uveoretinitis (EAU) in H-2b mice.

Beyond its role in disease induction, understanding these irbp peptide fragments is also critical for diagnostic and therapeutic advancements. For example, anti-IRBP antibody products are utilized in antigen-specific immunodetection in biological samples, aiding in the diagnosis and study of conditions related to IRBP. Furthermore, research is exploring the potential of specific IRBP derived peptide, R16 sequences as biologically active peptides with therapeutic implications.

The Interphotoreceptor Retinoid Binding Protein (IRBP) is not confined solely to the retina; IRBP is also present in the pineal gland, suggesting a broader physiological role beyond vision. This presence in the pineal gland can lead to pineal inflammation (EAP) in animals immunized with IRBP. The intricate functions of IRBP are still being unraveled, but current understanding suggests that IRBP plays a direct role in the release of all-trans retinol from the rods during operation of the visual cycle. This highlights its fundamental importance in maintaining visual function.

The study of human IRBP peptides 1-20 and other related fragments has provided valuable insights into the mechanisms of ocular inflammation and has opened avenues for developing targeted therapies. The ability of certain irbp peptide sequences to trigger specific immune responses makes them key targets for modulating the immune system to prevent or treat ocular inflammatory diseases. The continued investigation into IRBP (RBP3) and its various peptide components is essential for advancing our knowledge of retinal biology and developing effective interventions for vision-threatening conditions.